Mechelen, Belgium; October 17, 2022, 07.30 CET; – Galapagos NV ((Euronext &, NASDAQ:GLPG) announced today that it will host its 2022 R&D Day on Friday, November 4 for analysts, investors and the financial press 2022.

The live event will be held at the Yale Club in New York City from 8am to 10:30am EDT (1pm to 3:30pm CET). The event includes presentations from Key Opinion Leaders (KOLs) and management on the company’s strategic goals, scientific pipeline and commercial progress. The company will also discuss its third quarter financial results, which are expected to be released on November 3, 2022.

A live webcast of the event will be accessible via investor center on the company’s website and will be available for playback after the event. Interested parties can register for the webcast using the following link: Webcast Registrationand join the Q&A via conference call via the following link: Registration for conference calls.

Aover Galapagos
Galapagos is a fully integrated biotechnology company focused on the discovery, development and commercialization of innovative medicines. We are committed to improving the lives of patients worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio spans discovery to phase 4 programs in inflammation, oncology, fibrosis and other indications. Our first drug for rheumatoid arthritis and ulcerative colitis is available in the European Union, Norway, the UK and Japan. For more information, see www.glpg.com or continue to follow us LinkedIn or Twitter.

CContact
Galapagos R&D Update 2022 Contact:
Melody Carey
President and CEO
Rx Communications Group, LLC
mcarey@rxir.com

Investors:
Sophie van Gijsel
Head of Investor Relations
+1 781 296 1143

Sandra Cauwenberghs
Director Investor Relations
+32 495 58 46 63
ir@glpg.com

Media:
Marieke Vermeersch
Head of Corporate Communications
+32 479 490…